Showing 5741-5750 of 9771 results for "".
- Newborn Skin May Pave the Way Toward New Eczema Lotionhttps://practicaldermatology.com/news/newborn-skin-may-pave-the-way-for-new-eczema-lotion/2457844/Newborns emerge from the womb covered with a waxy substance called the vernix, which protects their skin from drying, and researchers have begun to realize that the vernix also helps babies adapt to life outside the womb by stimulating cells in the skin to make water-resistant lipid molecules.
- Differin Launches Retinoid Education Weekhttps://practicaldermatology.com/news/differin-launches-retinoid-education-week/2457848/Differin® has launched Retinoid Education Week to educate the more than 50 million Americans with acne about how retinoids can be used to treat their condition. Part of Nestlé Skin Health’s acne franchise, Differin is new to the over-the-counter acne category. However, retinoids
- Medimetriks Divests Xepi Cream to Cutanea Life Scienceshttps://practicaldermatology.com/news/medimetriks-divests-xepi-cream-to-cutanea-life-sciences/2457850/Medimetriks Pharmaceuticals, Inc. divested exclusive US rights for Xepi (ozenoxacin cream) 1% to Cutanea Life Sciences, Inc. for up to $30 million, with $29 million to be paid in 2018, plus the assumption of $5 mil
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- Skin Microbiome May Protect Against Skin Cancerhttps://practicaldermatology.com/news/skin-microbiome-may-protect-against-skin-cancer/2457857/Beneficial skin bacteria may protect against skin cancer, according to a new study in Science Advances. “We have identified a strain of Staphylococcus epidermidis, common on healthy human skin, that exerts a selective ability to inhibit the growth of some cancers,” sa
- DermTech Receives State of New York Laboratory Permithttps://practicaldermatology.com/news/dermtech-receives-state-of-new-york-laboratory-permit/2457864/DermTech, Inc., which specializes in non-invasive molecular dermatology, has received permitting from the State of New York, Department of Public Health. The addition of a New York permit to DermTech’s current accreditations, allows it to now provide laboratory services across the
- MainPointe Pharmaceuticals to Purchase and License Mission's Consumer Productshttps://practicaldermatology.com/news/mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products/2457868/Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa
- New DermTech Research Validates Gene Expression Against High-Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanomahttps://practicaldermatology.com/news/new-dermtech-research-validates-gene-expression-against-high-risk-dna-mutations-providing-objective-information-for-the-diagnosis-of-melanoma/2457871/DermTech, Inc. presented a late breaking abstract—“Validation of Noninvasive Gene Expression (PLA) Against High Risk Driver Mutations (BRAF, NRAS, and TERT) in Cutaneous Melanoma” —at the 76th Annual Meeting of the American Academy of Dermatology (AAD) in San Di
- New From BrandMD: Advanced Eyelash Growth Serumhttps://practicaldermatology.com/news/new-from-brandmd-advanced-eyelash-growth-serum/2457870/BrandMD's latest product, Advanced Eyelash Growth Serum, is now available. Advanced Eyelash Growth Serum has proven effective within as a little as two weeks of use, the company says. The proprietary formulation features a peptide complex, rich in Biochanin A, to help promo
- Asthma and Allergy Foundation Study Shows High Prevalence and QoL Impact for Adults with Atopic Dermatitishttps://practicaldermatology.com/news/asthma-and-allergy-foundation-study-shows-high-prevalence-and-qol-impact-for-adults-with-atopic-dermatitis/2457872/The Asthma and Allergy Foundation of America (AAFA) shared data demonstrating the high rate of prevalence of atopic dermatitis (AD) in the US adult population and a greater impact on health-related quality of life and mental health symptoms, such as depression and anxiety, for patients with moder